AstraZeneca stock falls after FDA panel votes against new cancer drug

In this article

Shares of AstraZeneca

turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug.

An advisory panel for the U.S. Food and Drug Administration late Thursday voted 6-3 against AstraZeneca’s oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design.

The FDA generally follows the recommendations of its advisory committees, but isn’t bound to.